C2Sense

C2Sense's Founding and Background

C2Sense was founded in 2013 as an MIT 'Tough Tech' spinout. The company has carved a niche for itself in the advanced optical sensing market. With its foundations in chemistry and optics, C2Sense has developed a reputation for creating revolutionary anti-counterfeiting and sensing solutions for various industries. The company’s technological advancements are built on state-of-the-art light-emitting materials and proprietary algorithms, transforming ordinary cameras into sophisticated measurement devices.

C2Sense's Halo Platform

In the medical field, C2Sense has innovated with its 'Halo' platform, which leverages fluorescence to convert traditional lateral flow assays into highly sensitive and machine-readable diagnostic tests. This platform is designed to offer unprecedented sensitivity and specificity at a low cost, thus enhancing the accuracy and accessibility of medical diagnostics. The Halo platform's utility extends to various applications, including trace oxygen detection in packaging and quality monitoring, ensuring product safety and efficacy.

C2Sense's Expertise and Innovation

C2Sense combines its expertise in chemistry, optics, and molecular sensing to offer customized solutions. The company’s technologies are designed to detect molecular activity and translate it into actionable data. By using molecular additives and proprietary software, C2Sense can sense subtle changes in a product and its environment, which is crucial for authentication, product viability assurance, and pathogen detection. Their materials can be integrated into products through various methods, such as flexographic printing and spray-coating, making the technology versatile and adaptable.

C2Sense's Intellectual Property and Funding

C2Sense holds 13 patents that cover the complexities of real-world optical sensing and the conversion of cameras into time-resolved fluorescence spectrometers. This robust intellectual property portfolio underscores the company's leadership in the field. Financially, C2Sense has been successful in securing funding to fuel its growth. The company completed the second closing of its $8M Series B round to accelerate the development of the Halo platform and previously secured $3.2 million in seed funding in 2017. Additionally, C2Sense received NIH RADx Tech funding to advance a digitally connected at-home diagnostic reader, further solidifying its position in the market.

C2Sense's Headquarters and Operational Base

C2Sense is headquartered at 480 Arsenal Way, Suite #110, Watertown, MA 02472. This location serves as the operational hub for the company's research, development, and administrative activities. Being situated in Watertown, MA, places C2Sense in proximity to several tech hubs and academic institutions, facilitating collaboration and innovation. The headquarters is equipped to support the company's mission of delivering highly sensitive and specific optical sensing solutions across various industries.